Skin Testing in Delayed Reactions to Drugs

Immunology and Allergy Clinics of North America

Volumn 29, Issue 3, 2009, Pages 517-535

  Barbaud, Annick ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Acute generalized exanthematous pustulosis; Antibiotics; Corticosteroids; Drug patch tests; Drug reaction with eosinophilia and systemic symptoms; Intradermal tests; Maculopapular rash; Toxic epidermal necrolysis (TEN)

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; BLEOMYCIN; CAPTOPRIL; CARBAMAZEPINE; CARBIMAZOLE; CELECOXIB; CHLOROQUINE; CIPROFLOXACIN; CLINDAMYCIN; COLCHICINE; CONTRAST MEDIUM; CORTICOSTEROID; COTRIMOXAZOLE; DESLORATADINE; DILTIAZEM; DIPYRONE; HEPARIN DERIVATIVE; METHOXSALEN; METRONIDAZOLE; MISOPROSTOL; MORPHINE; NIMESULIDE; PLATINUM COMPLEX; PSEUDOEPHEDRINE; SULFAMETHOXAZOLE; TETRAZEPAM; UNINDEXED DRUG; VANCOMYCIN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; CROSS REACTION; DELAYED HYPERSENSITIVITY; DIAGNOSTIC VALUE; DRUG HYPERSENSITIVITY; ECZEMA; FALSE POSITIVE RESULT; FIXED DRUG ERUPTION; HUMAN; INTRACUTANEOUS TEST; MACULOPAPULAR RASH; PATCH TEST; PREDICTION; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN ALLERGY; SKIN TEST; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; CROSS REACTIONS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEASIBILITY STUDIES; HUMANS; HYPERSENSITIVITY, DELAYED; PATCH TESTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 67649159972     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2009.04.010     Document Type: Review

References (127)

1. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 209 (2005) 209-216
2. Barbaud A., Reichert-Penetrat S., Trechot P., et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 139 (1998) 49-58
3. Barbaud A., Gonçalo M., Bruynzeel D., et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45 (2001) 321-328
4. Barbaud A. Drug skin tests and systemic drug reactions: an update. Expert Rev Dermatol 2 (2007) 481-495
5. Osawa J., Naito S., Aihara M., et al. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 17 (1990) 235-239
6. Bruynzeel D.P., and Van Ketel W.G. Patch testing in drug eruptions. Semin Dermatol 8 (1989) 196-203
7. Posadas S.J., and Pichler W.J. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 37 (2007) 989-999
8. Barbaud A. Tests cutanés dans l'investigation des toxidermies: de la physiopathologie aux résultats des investigations. Therapie 57 (2002) 258-262 [in French]
9. Alanko K., Stubb S., and Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 116 (1987) 561-567
10. Bruynzeel D.P., and Van Ketel W.G. Skin tests in the diagnosis of maculopapular drug eruptions. Semin Dermatol 6 (1987) 119-124
11. Romano A., Di Fonso M., Pietrantonio F., et al. Repeated patch testing in delayed hypersensitivity to beta-lactam antibiotics. Contact Dermatitis 28 (1993) 190
12. Felix R.H., and Comaish J.S. The value of the patch tests and other skin tests in drug eruptions. Lancet 1 (1974) 1017-1019
13. Barbaud A., Bene M.C., Schmutz J.L., et al. Role of delayed cellular hypersensitivity and adhesion molecules in maculopapular rashes induced by amoxicillin. Arch Dermatol 133 (1997) 481-486
14. Britschgi M., Steiner U.C., Schmid S., et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 107 (2001) 1433-1441
15. Brockow K., Romano A., Blanca M., et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57 (2002) 45-51
16. Kleinhans M., Linzbach L., Zedlitz S., et al. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 47 (2002) 100-102
17. Barbaud A., Bursztejn A.C., Schmutz J.L., et al. Patch tests with desloratadine at 10% induce false-positive results: test at 1%. J Eur Acad Dermatol Venereol 22 (2008) 1504-1505
18. Barbaud A., Trechot P., Reichert-Penetrat S., et al. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis 45 (2001) 265-268
19. Conilleau V., Dompmartin A., Michel M., et al. Photoscratch testing in systemic drug-induced photosensitivity. Photodermatol Photoimmunol Photomed 16 (2000) 62-66
20. Wilkinson D.S., Fregert S., Magnusson B., et al. Terminology of contact dermatitis. Acta Derm Venereol (Stockholm) 50 (1970) 287-292
21. Klein C.E., Trautmann A., Zillikens D., et al. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis 33 (1995) 448-449
22. Barbaud A., Trechot P., Reichert-Penetrat S., et al. Drug patch testing: the usefulness in testing on the most previously affected site in a systemic cutaneous adverse drug reaction to tetrazepam. Contact Dermatitis 44 (2001) 259-260
23. Ozkaya-Bayazit E., Bayazit H., and Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 41 (1999) 185-189
24. Schick E., Weber L., and Gall H. Topical and systemic provocation of fixed drug eruption due to phenazone. Contact Dermatitis 35 (1996) 58-59
25. Mahboob A., Haroon T.S., Iqbal Z., et al. Fixed drug eruption: topical provocation and subsequent phenomena. J Coll Physicians Surg Pak 16 (2006) 747-750
26. Sehgal V.N., and Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol 45 (2006) 897-908
27. Gupta R. Drugs causing fixed drug eruptions: confirmed by provocation tests. Indian J Dermatol Venereol Leprol 69 (2003) 120-121
28. Co Minh H.B., Bousquet P.J., Fontaine C., et al. Systemic reactions during skin tests with beta-lactams: a risk factor analysis. J Allergy Clin Immunol 117 (2006) 466-468
29. Romano A., Guéant-Rodriguez R.M., Viola M., et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 35 (2005) 1234-1242
30. Torres M.-J., Sanchez-Sabate E., Alvarez J., et al. Skin test evaluation in nonimmediate allergic reactions to penicillins. Clin Exp Allergy 59 (2004) 219-224
31. Lammintausta K., and Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 152 (2005) 968-974
32. Wolkenstein P., Chosidow O., Flechet M.-L., et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35 (1996) 234-236
33. Romano A., Viola M., Mondino C., et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int Arch Allergy Immunol 129 (2002) 169-174
34. Bernedo N., Gonzalez I., Gastaminza G., et al. Positive patch test in vancomycin allergy. Contact Dermatitis 45 (2001) 43
35. Padial A., Antunez C., Blanca-Lopez N., et al. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 38 (2008) 822-828
36. Barbaud A., Trechot P., Weber-Muller F., et al. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis 50 (2004) 22-26
37. Romano A., Di Fonso M., Papa G., et al. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy 50 (1995) 113-118
38. Leguy-Seguin V., Jolimoy G., Coudert B., et al. Diagnostic and predictive value of skin testing in platinum salts hypersensitivity. J Allergy Clin Immunol 119 (2007) 726-730
39. Brockow K., Becker E.W., Worret W.I., et al. Late skin test reactions to radiocontrast medium. J Allergy Clin Immunol 104 (1999) 1107-1108
40. Vernassiere C., Trechot P., Schmutz J.L., et al. Results and negative value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis 50 (2004) 359-366
41. Brockow K., Christiansen C., Kanny G., et al., ENDA; EAACI interest group on drug hypersensitivity. Management of hypersensitivity reactions to iodinated contrast media. Allergy 60 (2005) 150-158
42. Gueant-Rodriguez R.M., Romano A., Barbaud A., et al. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des 12 (2006) 3359-3372
43. Scherer K., Tsakiris D.A., and Bircher A.J. Hypersensitivity reactions to anticoagulant drugs. Curr Pharm Des 14 (2008) 2863-2873
44. Ludwig R.J., Beier C., Lindhoff-Last E., et al. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 49 (2003) 158-159
45. Akiyama M., Nakada T., Sueki H., et al. Drug eruption caused by non-ionic iodinated X-ray contrast media. Acad Radiol 5 (1998) S159-S161
46. Jappe U., Juschka U., Kuner N., et al. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 51 (2004) 67-72
47. Grange-Prunier A., Roth B., Kleinclaus I., et al. Pustulose exanthématique aigue generalisee due au carbimazole (Neomercazole): premier cas et valeur des patch tests. Ann Dermatol Venereol 133 (2006) 708-710 [in French]
48. Elston G.E., Johnston G.A., Mortimer N.J., et al. Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity. Clin Exp Dermatol 32 (2007) 52-53
49. Harries M.J., McIntyre S.J., and Kingston T.P. Co-amoxiclav-induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis 55 (2006) 372
50. Altaykan A., Boztepe G., Erkin G., et al. Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing. J Dermatolog Treat 15 (2004) 231-234
51. Hausermann P., Scherer K., Weber M., et al. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. Dermatology 211 (2005) 277-280
52. Valois M., Phillips E.J., Shear N.H., et al. Clindamycin-associated acute generalized exanthematous pustulosis. Contact Dermatitis 48 (2003) 169
53. Buettiker U., Keller M., Pichler W.J., et al. Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group a confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology 213 (2006) 40-43
54. Girardi M., Duncan K.O., Tigelaar R.E., et al. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol 27 (2005) 343-346
55. Gonzalo-Garijo M.A., Pérez-Calderón R., De Argila D., et al. Metamizole-induced acute generalized exanthematous pustulosis. Contact Dermatitis 49 (2003) 47-48
56. Morant C., Devis T., Alcaraz I., et al. Pustulose exanthématique aigue généralisée au méthoxalène (Méladinine) avec positivité des tests épicutanés. Ann Dermatol Venereol 129 (2002) 234-235 [in French]
57. Kardaun S.H., and de Monchy J.G. Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test. J Am Acad Dermatol 55 (2006) S21-S23
58. Teixeira M., Silva E., and Selores M. Acute generalized exanthematous pustulosis induced by nimesulide. Dermatol Online J 12 (2006) 20
59. Mayo-Pampín E., Flórez A., Feal C., et al. Acute generalized exanthematous pustulosis due to pseudoephedrine with positive patch test. Acta Derm Venereol 86 (2006) 542-543
60. Padial M.A., Alvarez-Ferreira J., Tapia B., et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol 150 (2004) 139-142
61. Martínez M.B., Salvador J.F., Aguilera G.V., et al. Acute generalized exanthematous pustulosis induced by ranitidine hydrochloride. Arch Dermatol 139 (2003) 1181-1183
62. Thomas E., Bellón T., Barranco P., et al. Acute generalized exanthematous pustulosis due to tetrazepam. J Investig Allergol Clin Immunol 18 (2008) 119-122
63. Komericki P., Grims R., Kränke B., et al. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol 57 (2007) 718-721
64. Anliker M.D., and Wüthrich B. Acute generalized exanthematous pustulosis due to sulfamethoxazol with positive lymphocyte transformation test (LTT). J Investig Allergol Clin Immunol 13 (2003) 66-68
65. Lee J.H., Park H.K., Heo J., et al. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 23 (2008) 521-525
66. Aouam K., Bel Hadj Ali H., Youssef M., et al. Carbamazepine-induced DRESS and HHV6 primary infection: the importance of skin tests. Epilepsia 49 (2008) 1630-1633
67. Gaig P., García-Ortega P., Baltasar M., et al. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol 16 (2006) 321-326
68. Antunes A., Davril A., Trechot P., et al. Syndrome d'hypersensibilité à la minocycline. Ann Dermatol Venereol 126 (1999) 518-521 [in French]
69. Suswardana, Hernanto M., Yudani B.A., et al. DRESS syndrome from cefadroxil confirmed by positive patch test. Allergy 62 (2007) 1216-1217
70. Caboni S., Gunera-Saad N., Ktiouet-Abassi S., et al. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy 62 (2007) 1342-1343
71. ®). Positivité des tests épicutanés. Ann Dermatol Venereol 132 (2005) 1000-1002 [in French]
72. Ghislain P.D., Bodarwe A.D., Vanderdonckt O., et al. Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome. Acta Derm Venereol 84 (2004) 65-68
73. Romano A., Di Fonso M., Pocobelli D., et al. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. J Investig Allergol Clin Immunol 3 (1993) 53-55
74. Tagami H., Tatsuta K., Iwatski K., et al. Delayed hypersensitivity in ampicillin-induced toxic epidermal necrolysis. Arch Dermatol 119 (1983) 910-913
75. Friedmann P.S., Strickland I., Pirmohamed M., et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 130 (1994) 598-604
76. Nagge J.J., Knowles S.R., Juurlink D.N., et al. Pseudoephedrine-induced toxic epidermal necrolysis. Arch Dermatol 141 (2005) 907-908
77. Goossens C., Sass U., and Song M. Baboon syndrome. Dermatology 194 (1997) 421-422
78. Barbaud A., Trechot P., Granel F., et al. A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis. Dermatology 199 (1999) 258-260
79. Arnold A.W., Hausermann P., Bach S., et al. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology 214 (2007) 89-93
80. Gallo R., and Parodi A. Baboon syndrome from 5-aminosalicylic acid. Contact Dermatitis 46 (2002) 110
81. Sánchez T.S., Sánchez-Pérez J., Aragüés M., et al. Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis 42 (2000) 312-313
82. Wolf R., Orion E., and Matz H. The baboon syndrome or intertriginous drug eruption. a report of eleven cases and a second look at its pathomechanism. Dermatol Online J 9 (2003) 2
83. Herfs H., Schirren C.G., Przybilla B., et al. Das "baboon-syndrom". Hautarzt 44 (1993) 466-469
84. Sans V., Jouary T., Hubiche T., et al. Baboon syndrome induced by cetuximab. Arch Dermatol 144 (2008) 272-274
85. Kick G., and Przybilla B. Delayed prick test reaction identifies amoxicillin as elicitor of baboon syndrome. Contact Dermatitis 43 (2000) 366-367
86. Handisurya A., Stingl G., and Wöhrl S. SDRIFE (baboon syndrome) induced by penicillin. Clin Exp Dermatol 34 (2009) 355-357
87. Lammintausta K., Mäkela L., and Kalimo K. Rapid systemic valaciclovir reaction subsequent to aciclovir contact allergy. Contact Dermatitis 45 (2001) 181
88. Vernassiere C., Barbaud A., Trechot P.H., et al. Systemic acyclovir reaction subsequent to acyclovir contact allergy: which systemic antiviral drug should then be used?. Contact Dermatitis 49 (2003) 155-157
89. Sakakibara T., Hata M., Numano K., et al. Fixed-drug eruption caused by allylisopropylacetylurea. Contact Dermatitis 44 (2001) 189-190
90. Gaig P., San Miguel-Moncin M.M., Bartra J., et al. Usefulness of patch tests for diagnosing selective allergy to captopril. J Investig Allergol Clin Immunol 11 (2001) 204-206
91. Lee A.Y., Choi J., and Chey W.Y. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 48 (2003) 137-139
92. Kawada A., Aragane Y., Maeda A., et al. Drug eruption induced by cefcapene pivoxil hydrochloride. Contact Dermatitis 44 (2001) 197
93. Verbeiren S., Morant C., Charlanne H., et al. Toxidermie due au celecoxib avec tests épicutané positif. Ann Dermatol Venereol 129 (2002) 203-205 [in French]
94. Brown V.L., and Orton D.I. Cutaneous adverse drug reaction to oral chlorphenamine detected with patch testing. Contact Dermatitis 52 (2005) 49-50
95. Machet L., Vaillant L., Dardaine V., et al. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis 26 (1992) 347-348
96. Estrada J.L., Alvarez Puebla M.J., Ortiz de Urbina J.J., et al. Generalized eczema due to codeine. Contact Dermatitis 44 (2001) 185
97. Kilpio K., and Hannuksela M. Corticosteroid allergy in asthma. Allergy 58 (2003) 1131-1135
98. Jonker M.J., and Bruynzeel D. Anaphylactic reaction elicited by patch testing with diclofenac. Contact Dermatitis 49 (2003) 114-115
99. Cholez C., Trechot P., Schmutz J.L., et al. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy 58 (2003) 1207-1209
100. Rodriguez-Morales A., Alonso Llamazares A., Palacios Benito R., et al. Fixed drug eruption from quinolones with a positive lesional patch test to ciprofloxacin. Contact Dermatitis 44 (2001) 255
101. Rebello S., Sanchez P., Vega J.M., et al. Hypersensitivity syndrome from isoniazid with positive patch test. Contact Dermatitis 45 (2001) 306
102. Quinones Estevez D., and Fernandez Schmitz C. Exanthema to metamizole. Allergy 56 (2001) 262-263
103. Sasaki K., Yamamoto T., Kishi M., et al. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol 11 (2001) 469-471
104. Malheiro D., Cadinha S., Rodrigues J., et al. Nimesulide-induced fixed drug eruption. Allergol Immunopathol (Madr) 33 (2005) 285-287
105. Barranco R., Tornero P., De Barrio M., et al. Type IV hypersensitivity to oral nystatin. Contact Dermatitis 45 (2001) 60
106. Montoro J., Diaz M., Genis C., et al. Non-pigmenting cutaneous-mucosal fixed drug eruption due to piroxicam. Allergol Immunopathol 31 (2003) 53-55
107. Trujillo M.J., de Barrio M., Rodriguez A., et al. Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report. Allergol Immunopathol (Madr) 29 (2001) 133-136
108. Gonçalo M., and Figueiredo A. Cross-reactions among oxicams in cutaneous adverse drug reactions. Contact Dermatitis 46 (2002) S31
109. Mashiah J., and Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 139 (2003) 1181-1183
110. Strauss R.M., Green S.T., and Gawkrodger D.J. Rifampicin allergy confirmed by an intradermal test, but with a negative patch test. Contact Dermatitis 45 (2001) 108
111. Pirker C., Misic A., Brinkmeier T., et al. Tetrazepam drug sensitivity - usefulness of the patch test. Contact Dermatitis 47 (2002) 135-138
112. Wong D.A., and Freeman S. Cutaneous allergic reaction to intramuscular vitamin K1. Australas J Dermatol 40 (1999) 147-152
113. Antunez C., Martin E., Cornejo-Garcia J.A., et al. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des 12 (2006) 3327-3333
114. Bonadonna P., Schiappoli M., Senna G., et al. Delayed selective reaction to clavulanic acid: a case report. J Investig Allergol Clin Immunol 15 (2005) 302-304
115. Romano A., Quaratino D., Papa G., et al. Aminopenicillin allergy. Arch Dis Child 76 (1997) 513-517
116. Ponvert C., Weilenmann C., Wassenberg J., et al. Allergy to betalactam antibiotics in children: a prospective follow-up study in retreated children after negative responses in skin and challenge tests. Allergy 62 (2007) 42-46
117. Berkun Y., Ben-Zvi A., Levy Y., et al. Evaluation of adverse reactions to local anesthetics: experience with 236 patients. Ann Allergy Asthma Immunol 91 (2003) 342-345
118. Padial A., Posadas S., Alvarez J., et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy 60 (2005) 665-670
119. Ludwig R.J., Schindewolf M., Alban S., et al. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 94 (2005) 1265-1269
120. Ludwig R.J., Schindewolf M., Utikal J., et al. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 96 (2006) 611-617
121. Gerhardt A., Zotz R.B., Stockschlaeder M., et al. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 97 (2007) 496-497
122. Adachi A., Fukunaga A., and Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin. Int J Dermatol 43 (2004) 597-599
123. Lee A.Y., Chey W.Y., Choi J., et al. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 82 (2002) 114-117
124. Schmid D.A., Depta J.P., and Pichler W.J. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 36 (2006) 59-69
125. Barranco R., Rodriguez A., de Barrio M., et al. Sympathomimetic drug allergy: cross-reactivity study by patch test. Am J Clin Dermatol 5 (2004) 351-355
126. Waton J., Tréchot P., Loss-Ayav C., et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol 160 (2009) 786-794
127. Ulrich G., Schmutz J.L., Trechot P., et al. Sensitization to petrolatum: an unusual cause of false positive drug patch tests. Allergy 59 (2004) 1006-1009